과제정보
This work was supported by a research fund (NCC-2112570-3) of National Cancer Center, Republic of Korea.
참고문헌
- Choi M, Kim NS, Sheen SS, Ki SM, Lee SJ, Kim JY. The status and dissemination plan of clinical practice guideline in Korea. NECA, 2015.
- Choi M, Kim NS, Jung Y, Lee SJ, Son SK, Lyu DH. Promoting the quality of medicine: based on clinical practice guidelines. NECA, 2015.
- Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. Development of the AGREE II, part 1: performance, usefulness and areas for improvement. CMAJ 2010;182:1045-1052.
- Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. Development of the AGREE II, part 2: assessment of validity of items and tools to support application. CMAJ 2010;182:E472-478.
- Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol 2013;66:408-414.
- Scottish Intercollegiate Guidelines Network (Sign). SIGN 50: a guideline developer's handbook.: SIGN, 2014.
- Schunemann H, Brozek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach 2013 [cited 2013 Oct]. Available from: https://gdt.gradepro.org/app/handbook/handbook.html.
- Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-926.
- Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is "quality of evidence" and why is it important to clinicians? BMJ 2008;336:995-998.
- Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. Going from evidence to recommendations. BMJ 2008;336:1049-1051.
- Schunemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008;336:1106-1110.
- Clayton RA, Clarke DL, Currie EJ, Madhavan KK, Parks RW, Garden OJ. Incidence of benign pathology in patients undergoing hepatic resection for suspected malignancy. Surgeon 2003;1:32-38.
- Scheuermann U, Widyaningsih R, Hoppe-Lotichius M, Heise M, Otto G. Detection of benign hilar bile duct stenoses - A retrospective analysis in 250 patients with suspicion of Klatskin tumour. Ann Med Surg (Lond) 2016;8:43-49.
- Dumonceau JM, Delhaye M, Charette N, Farina A. Challenging biliary strictures: pathophysiological features, differential diagnosis, diagnostic algorithms, and new clinically relevant biomarkers - part 1. Therap Adv Gastroenterol 2020;13:1756284820927292.
- Shanmugarajah I, Solhaug M, Aslam O, Reiertsen O. Efficacy and safety assessment of ERCP in patients with malignant biliary obstruction. Acta Gastroenterol Belg 2017;80:487-491.
- Akita M, Ajiki T, Matsumoto T, Shinozaki K, Goto T, Asari S, et al. Preoperative cholangitis affects survival outcome in patients with extrahepatic bile duct cancer. J Gastrointest Surg 2017;21:983-989.
- Cillo U, Fondevila C, Donadon M, Gringeri E, Mocchegiani F, Schlitt HJ, et al. Surgery for cholangiocarcinoma. Liver Int 2019;39 Suppl 1:143-155.
- Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M, Vauthey JN. Hilar cholangiocarcinoma: expert consensus statement. HPB (Oxford) 2015;17:691-699.
- Lau SH, Lau WY. Current therapy of hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2012;11:12-17.
- Ishii Y, Sasaki T, Serikawa M, Kobayashi K, Kamigaki M, Minami T, et al. Characteristic features of cholangiocarcinoma complicating primary sclerosing cholangitis. Hepatogastroenterology 2014;61:567-573.
- Kuzu UB, Odemis B, Suna N, Yildiz H, Parlak E, Disibeyaz S, et al. The detection of cholangiocarcinoma in primary sclerosing cholangitis patients: single center experience. J Gastrointest Cancer 2016;47:8-14.
- Hultcrantz R, Olsson R, Danielsson A, Jarnerot G, Loof L, Ryden BO, et al. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 1999;30:669-673.
- Fisher A, Theise ND, Min A, Mor E, Emre S, Pearl A, et al. CA19-9 does not predict cholangiocarcinoma in patients with primary sclerosing cholangitis undergoing liver transplantation. Liver Transpl Surg 1995;1:94-98.
- John AR, Haghighi KS, Taniere P, Esmat ME, Tan YM, Bramhall SR. Is a raised CA 19-9 level diagnostic for a cholangiocarcinoma in patients with no history of sclerosing cholangitis? Dig Surg 2006;23:319-324.
- Patel AH, Harnois DM, Klee GG, Larusso NF, Gores GJ. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000;95:204-207.
- Hu C, Zhang Y, Zhang M, Li T, Zheng X, Guo Q, et al. Exosomal Cripto-1 serves as a potential biomarker for perihilar cholangiocarcinoma. Front Oncol 2021;11:730615.
- Liang B, Zhong L, He Q, Wang S, Pan Z, Wang T, et al. Diagnostic accuracy of serum CA19-9 in patients with cholangiocarcinoma: a systematic review and meta-analysis. Med Sci Monit 2015;21:3555-3563.
- Tshering G, Dorji PW, Chaijaroenkul W, Na-Bangchang K. Biomarkers for the diagnosis of cholangiocarcinoma: a systematic review. Am J Trop Med Hyg 2018;98:1788-1797.
- Loosen SH, Roderburg C, Kauertz KL, Koch A, Vucur M, Schneider AT, et al. CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma. Sci Rep 2017;7:16975.
- Prachayakul V, Rugivarodom M, Nopjaroonsri P, Cheirsilpa K, Chang A, Kamolhan T, et al. Diagnostic power of DNA methylation markers suggestive of cholangiocarcinoma in ERCP-based brush cytology. Gastrointest Endosc 2022;95:123-130.e1.
- Leelawat K, Narong S, Wannaprasert J, Leelawat S. Serum NGAL to clinically distinguish cholangiocarcinoma from benign biliary tract diseases. Int J Hepatol 2011;2011:873548.
- Salem PES, Ghazala RA, El Gendi AM, Emara DM, Ahmed NM. The association between circulating MicroRNA-150 level and cholangiocarcinoma. J Clin Lab Anal 2020;34:e23397.
- Gul-Utku O, Karatay E, Ergul B, Kisa Þ, Erdin Z, Oguz D. The Role of Resolvin D1 in the differential diagnosis of the cholangiocarcinoma and benign biliary diseases. Clin Lab 2020;66.
- Leelawat K, Narong S, Wannaprasert J, Ratanashu-Ek T. Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma. World J Gastroenterol 2010;16:4697-4703.
- Wintachai P, Lim JQ, Techasen A, Lert-Itthiporn W, Kongpetch S, Loilome W, et al. Diagnostic and prognostic value of circulating cell-free dna for cholangiocarcinoma. Diagnostics (Basel) 2021;11:999.
- Silsirivanit A, Matsuda A, Kuno A, Tsuruno C, Uenoyama Y, Seubwai W, et al. Multi-serum glycobiomarkers improves the diagnosis and prognostic prediction of cholangiocarcinoma. Clin Chim Acta 2020;510:142-149.
- Yamaguchi T, Yokoyama Y, Ebata T, Matsuda A, Kuno A, Ikehara Y, et al. Verification of WFA-sialylated MUC1 as a sensitive biliary biomarker for human biliary tract cancer. Ann Surg Oncol 2016;23:671-677.
- Tangkijvanich P, Thong-Ngam D, Theamboonlers A, Hanvivatvong O, Kullavanijaya P, Poovorawan Y. Diagnostic role of serum interleukin 6 and CA 19-9 in patients with cholangiocarcinoma. Hepatogastroenterology 2004;51:15-19.
- Ke W, Zeng L, Hu Y, Chen S, Tian M, Hu Q. Detection of early-stage extrahepatic cholangiocarcinoma in patients with biliary strictures by soluble B7-H4 in the bile. Am J Cancer Res 2018;8:699-707.
- Kato Y, Takahashi S, Gotohda N, Konishi M. prognostic impact of the initial postoperative CA19-9 level in patients with extrahepatic bile duct cancer. J Gastrointest Surg 2016;20:1435-1443.
- Tella SH, Kommalapati A, Yadav S, Bergquist JR, Goyal G, Durgin L, et al. Novel staging system using carbohydrate antigen (CA) 19-9 in extra-hepatic cholangiocarcinoma and its implications on overall survival. Eur J Surg Oncol 2020;46:789-795.
- Xu S, Zhang XP, Zhao GD, Zhao ZM, Gao YX, Hu MG, et al. Development and validation of an online calculator to predict early recurrence and long-term survival in patients with distal cholangiocarcinoma after pancreaticoduodenectomy. J Hepatobiliary Pancreat Sci 2022;29:1214-1225.
- Juntermanns B, Radunz S, Heuer M, Hertel S, Reis H, Neuhaus JP, et al. Tumor markers as a diagnostic key for hilar cholangiocarcinoma. Eur J Med Res 2010;15:357-361.
- Padthaisong S, Thanee M, Namwat N, Phetcharaburanin J, Klanrit P, Khuntikeo N, et al. Overexpression of a panel of cancer stem cell markers enhances the predictive capability of the progression and recurrence in the early stage cholangiocarcinoma. J Transl Med 2020;18:64.
- Menzel J, Poremba C, Dietl KH, Domschke W. Preoperative diagnosis of bile duct strictures--comparison of intraductal ultrasonography with conventional endosonography. Scand J Gastroenterol 2000;35:77-82.
- Fernandez-Esparrach G, Gines A, Sanchez M, Pages M, Pellise M, Fernandez-Cruz L, et al. Comparison of endoscopic ultrasonography and magnetic resonance cholangiopancreatography in the diagnosis of pancreatobiliary diseases: a prospective study. Am J Gastroenterol 2007;102:1632-1639.
- Sai JK, Suyama M, Kubokawa Y, Watanabe S, Maehara T. Early detection of extrahepatic bile-duct carcinomas in the nonicteric stage by using MRCP followed by EUS. Gastrointest Endosc 2009;70:29-36.
- Heinzow HS, Kammerer S, Rammes C, Wessling J, Domagk D, Meister T. Comparative analysis of ERCP, IDUS, EUS and CT in predicting malignant bile duct strictures. World J Gastroenterol 2014;20:10495-10503.
- Sotoudehmanesh R, Nejati N, Farsinejad M, Kolahdoozan S. Efficacy of endoscopic ultrasonography in evaluation of undetermined etiology of common bile duct dilatation on abdominal ultrasonography. Middle East J Dig Dis 2016;8:267-272.
- Malik S, Kaushik N, Khalid A, Bauer K, Brody D, Slivka A, et al. EUS yield in evaluating biliary dilatation in patients with normal serum liver enzymes. Dig Dis Sci 2007;52:508-512.
- Saifuku Y, Yamagata M, Koike T, Hitomi G, Kanke K, Watanabe H, et al. Endoscopic ultrasonography can diagnose distal biliary strictures without a mass on computed tomography. World J Gastroenterol 2010;16:237-244.
- Tamada K, Ushio J, Sugano K. Endoscopic diagnosis of extrahepatic bile duct carcinoma: advances and current limitations. World J Clin Oncol 2011;2:203-216.
- Fritscher-Ravens A, Broering DC, Knoefel WT, Rogiers X, Swain P, Thonke F, et al. EUS-guided fine-needle aspiration of suspected hilar cholangiocarcinoma in potentially operable patients with negative brush cytology. Am J Gastroenterol 2004;99:45-51.
- Eloubeidi MA, Chen VK, Jhala NC, Eltoum IE, Jhala D, Chhieng DC, et al. Endoscopic ultrasound-guided fine needle aspiration biopsy of suspected cholangiocarcinoma. Clin Gastroenterol Hepatol 2004;2:209-213.
- Weilert F, Bhat YM, Binmoeller KF, Kane S, Jaffee IM, Shaw RE, et al. EUS-FNA is superior to ERCP-based tissue sampling in suspected malignant biliary obstruction: results of a prospective, single-blind, comparative study. Gastrointest Endosc 2014;80:97-104.
- Dewitt J, Misra VL, Leblanc JK, Mchenry L, Sherman S. EUS-guided FNA of proximal biliary strictures after negative ERCP brush cytology results. Gastrointest Endosc 2006;64:325-333.
- Navaneethan U, Njei B, Venkatesh PG, Lourdusamy V, Sanaka MR. Endoscopic ultrasound in the diagnosis of cholangiocarcinoma as the etiology of biliary strictures: a systematic review and meta-analysis. Gastroenterol Rep (Oxf) 2015;3:209-215.
- Tamada K, Kanai N, Tomiyama T, Ohashi A, Wada S, Satoh Y, et al. Prediction of the histologic type of bile duct cancer by using intra-ductal ultrasonography. Abdom Imaging 1999;24:484-490.
- Tamada K, Nagai H, Yasuda Y, Tomiyama T, Ohashi A, Wada S, et al. Transpapillary intraductal US prior to biliary drainage in the assessment of longitudinal spread of extrahepatic bile duct carcinoma. Gastrointest Endosc 2001;53:300-307.
- Domagk D, Poremba C, Dietl KH, Senninger N, Heinecke A, Domschke W, et al. Endoscopic transpapillary biopsies and intraductal ultrasonography in the diagnostics of bile duct strictures: a prospective study. Gut 2002;51:240-244.
- Farrell RJ, Agarwal B, Brandwein SL, Underhill J, Chuttani R, Pleskow DK. Intraductal US is a useful adjunct to ERCP for distinguishing malignant from benign biliary strictures. Gastrointest Endosc 2002;56:681-687.
- Nakai Y, Isayama H, Tsujino T, Kawabe T, Yashima Y, Yagioka H, et al. Intraductal US in the assessment of tumor involvement to the orifice of the cystic duct by malignant biliary obstruction. Gastrointest Endosc 2008;68:78-83.
- Kim HM, Park JY, Kim KS, Park MS, Kim MJ, Park YN, et al. Intra-ductal ultrasonography combined with percutaneous transhepatic cholangioscopy for the preoperative evaluation of longitudinal tumor extent in hilar cholangiocarcinoma. J Gastroenterol Hepatol 2010;25:286-292.
- Choi ER, Chung YH, Lee JK, Lee KT, Lee KH, Choi DW, et al. Preoperative evaluation of the longitudinal extent of borderline resectable hilar cholangiocarcinoma by intraductal ultrasonography. J Gastroenterol Hepatol 2011;26:1804-1810.
- Meister T, Heinzow HS, Woestmeyer C, Lenz P, Menzel J, Kucharzik T, et al. Intraductal ultrasound substantiates diagnostics of bile duct strictures of uncertain etiology. World J Gastroenterol 2013;19:874-881.
- Vazquez-Sequeiros E, Baron TH, Clain JE, Gostout CJ, Norton ID, Petersen BT, et al. Evaluation of indeterminate bile duct strictures by intraductal US. Gastrointest Endosc 2002;56:372-379.
- Moon JH, Ko BM, Choi HJ, Hong SJ, Cheon YK, Cho YD, et al. Intraductal balloon-guided direct peroral cholangioscopy with an ultraslim upper endoscope (with videos). Gastrointest Endosc 2009;70:297-302.
- Teng F, Tang YY, Dai JL, Li Y, Chen ZY. The effect and safety of preoperative biliary drainage in patients with hilar cholangiocarcinoma: an updated meta-analysis. World J Surg Oncol 2020;18:174.
- Mehrabi A, Khajeh E, Ghamarnejad O, Nikdad M, Chang DH, Buchler MW, et al. Meta-analysis of the efficacy of preoperative biliary drainage in patients undergoing liver resection for perihilar cholangiocarcinoma. Eur J Radiol 2020;125:108897.
- Celotti A, Solaini L, Montori G, Coccolini F, Tognali D, Baiocchi G. Preoperative biliary drainage in hilar cholangiocarcinoma: systematic review and meta-analysis. Eur J Surg Oncol 2017;43:1628-1635.
- Kimura N, Young AL, Toyoki Y, Wyatt JI, Toogood GJ, Hidalgo E, et al. Radical operation for hilar cholangiocarcinoma in comparable Eastern and Western centers: outcome analysis and prognostic factors. Surgery 2017;162:500-514.
- El-Hanafy E. Pre-operative biliary drainage in hilar cholangiocarcinoma, benefits and risks, single center experience. Hepatogastroenterology 2010;57:414-419.
- Farges O, Regimbeau JM, Fuks D, Le Treut YP, Cherqui D, Bachellier P, et al. Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma. Br J Surg 2013;100:274-283.
- Giuliante F, Ardito F, Aldrighetti L, Ferrero A, Pinna AD, De Carlis L, et al. Liver resection for perihilar cholangiocarcinoma: impact of biliary drainage failure on postoperative outcome. Results of an Italian multicenter study. Surgery 2021;170:383-389.
- Higuchi R, Yazawa T, Uemura S, Izumo W, Chaudhary RJ, Furukawa T, et al. ENBD is associated with decreased tumor dissemination compared to ptbd in perihilar cholangiocarcinoma. J Gastrointest Surg 2017;21:1506-1514.
- Xiong JJ, Nunes QM, Huang W, Pathak S, Wei AL, Tan CL, et al. Preoperative biliary drainage in patients with hilar cholangiocarcinoma undergoing major hepatectomy. World J Gastroenterol 2013;19:8731-8739.
- Dinant S, Gerhards MF, Rauws EA, Busch OR, Gouma DJ, Van Gulik TM. Improved outcome of resection of hilar cholangiocarcinoma (Klatskin tumor). Ann Surg Oncol 2006;13:872-880.
- Ercolani G, Zanello M, Grazi GL, Cescon M, Ravaioli M, Del Gaudio M, et al. Changes in the surgical approach to hilar cholangiocarcinoma during an 18-year period in a Western single center. J Hepatobiliary Pancreat Sci 2010;17:329-337.
- Gerhards MF, Van Gulik TM, De Wit LT, Obertop H, Gouma DJ. Evaluation of morbidity and mortality after resection for hilar cholangiocarcinoma--a single center experience. Surgery 2000;127:395-404.
- Ratti F, Cipriani F, Fiorentini G, Hidalgo Salinas C, Catena M, Paganelli M, et al. Management of hilum infiltrating tumors of the liver: the impact of experience and standardization on outcome. Dig Liver Dis 2019;51:135-141.
- Zhang XF, Beal EW, Merath K, Ethun CG, Salem A, Weber SM, et al. Oncologic effects of preoperative biliary drainage in resectable hilar cholangiocarcinoma: percutaneous biliary drainage has no adverse effects on survival. J Surg Oncol 2018;117:1267-1277.
- Ferrero A, Lo Tesoriere R, Vigano L, Caggiano L, Sgotto E, Capussotti L. Preoperative biliary drainage increases infectious complications after hepatectomy for proximal bile duct tumor obstruction. World J Surg 2009;33:318-325.
- Parks RW, Currie EJ, Madhavan KK, Garden OJ. Increased bacterobilia associated with preoperative biliary drainage in patients with hilar cholangiocarcinoma. HPB 2000;2:375-381.
- Cai Y, Tang Q, Xiong X, Li F, Ye H, Song P, et al. Preoperative biliary drainage versus direct surgery for perihilar cholangiocarcinoma: a retrospective study at a single center. Biosci Trends 2017;11:319-325.
- Figueras J, Llado L, Valls C, Serrano T, Ramos E, Fabregat J, et al. Changing strategies in diagnosis and management of hilar cholangiocarcinoma. Liver Transpl 2000;6:786-794.
- Ten Hoopen-Neumann H, Gerhards MF, Van Gulik TM, Bosma A, Verbeek PC, Gouma DJ. Occurrence of implantation metastases after resection of Klatskin tumors. Dig Surg 1999;16:209-213.
- Kennedy TJ, Yopp A, Qin Y, Zhao B, Guo P, Liu F, et al. Role of preoperative biliary drainage of liver remnant prior to extended liver resection for hilar cholangiocarcinoma. HPB (Oxford) 2009;11:445-451.
- Nuzzo G, Giuliante F, Ardito F, Giovannini I, Aldrighetti L, Belli G, et al. Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg 2012;147:26-34.
- Wiggers JK, Groot Koerkamp B, Cieslak KP, Doussot A, Van Klaveren D, Allen PJ, et al. Postoperative mortality after liver resection for perihilar cholangiocarcinoma: development of a risk score and importance of biliary drainage of the future liver remnant. J Am Coll Surg 2016;223:321-331.e1.
- Ribero D, Zimmitti G, Aloia TA, Shindoh J, Fabio F, Amisano M, et al. Preoperative cholangitis and future liver remnant volume determine the risk of liver failure in patients undergoing resection for hilar cholangiocarcinoma. J Am Coll Surg 2016;223:87-97.
- Song SC, Choi DW, Kow AW, Choi SH, Heo JS, Kim WS, et al. Surgical outcomes of 230 resected hilar cholangiocarcinoma in a single centre. ANZ J Surg 2013;83:268-274.
- Su CH, Tsay SH, Wu CC, Shyr YM, King KL, Lee CH, et al. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg 1996;223:384-394.
- Nakanuma Y, Sato Y, Harada K, Sasaki M, Xu J, Ikeda H. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol 2010;2:419-427.
- Mills SE, Cater D, Greenson JK, Reuter VE, Stoler MH. Sternberg's diagnostic surgical pathology. 5th ed.: Lippincott Williams & Wilkins, 2010.
- Gore RM, Fulcher AS, Taylor AJ, Ghahremani GG. Anomalies and anatomic variants of the gallbladder and biliary tract. In: Gore RM, Levine MS, ed. Textbook of gastrointestinal radiology. 3rd ed.: Elsevier, 2008:1403-1404.
- Turner MA, Fulcher AS. The cystic duct: normal anatomy and disease processes. Radiographics 2001;21:3-22; questionnaire 288-294.
- Sarawagi R, Sundar S, Gupta SK, Raghuwanshi S. Anatomical variations of cystic ducts in magnetic resonance cholangiopancreatography and clinical implications. Radiol Res Pract 2016;2016:3021484.
- Ruys AT, Van Beem BE, Engelbrecht MR, Bipat S, Stoker J, Van Gulik TM. Radiological staging in patients with hilar cholangiocarcinoma: a systematic review and meta-analysis. Br J Radiol 2012;85:1255-1262.
- Park HS, Lee JM, Choi JY, Lee MW, Kim HJ, Han JK, et al. Preoperative evaluation of bile duct cancer: MRI combined with MR cholangiopancreatography versus MDCT with direct cholangiography. AJR Am J Roentgenol 2008;190:396-405.
- Akamatsu N, Sugawara Y, Osada H, Okada T, Itoyama S, Komagome M, et al. Preoperative evaluation of the longitudinal spread of extrahepatic bile duct cancer using multidetector computed tomography. J Hepatobiliary Pancreat Surg 2009;16:216-222.
- Cho ES, Park MS, Yu JS, Kim MJ, Kim KW. Biliary ductal involvement of hilar cholangiocarcinoma: multidetector computed tomography versus magnetic resonance cholangiography. J Comput Assist Tomogr 2007;31:72-78.
- Han JK, Choi BI, Kim AY, An SK, Lee JW, Kim TK, et al. Cholangiocarcinoma: pictorial essay of CT and cholangiographic findings. Radiographics 2002;22:173-187.
- Choi BI, Lee JM, Han JK. Imaging of intrahepatic and hilar cholangiocarcinoma. Abdom Imaging 2004;29:548-557.
- Park HS, Lee JM, Kim SH, Jeong JY, Kim YJ, Lee KH, et al. CT Differentiation of cholangiocarcinoma from periductal fibrosis in patients with hepatolithiasis. AJR Am J Roentgenol 2006;187:445-453.
- Choi YH, Lee JM, Lee JY, Han CJ, Choi JY, Han JK, et al. Biliary malignancy: value of arterial, pancreatic, and hepatic phase imaging with multidetector-row computed tomography. J Comput Assist Tomogr 2008;32:362-368.
- Park HJ, Kim SH, Jang KM, Choi SY, Lee SJ, Choi D. The role of diffusion-weighted MR imaging for differentiating benign from malignant bile duct strictures. Eur Radiol 2014;24:947-958.
- Park MS, Kim TK, Kim KW, Park SW, Lee JK, Kim JS, et al. Differentiation of extrahepatic bile duct cholangiocarcinoma from benign stricture: findings at MRCP versus ERCP. Radiology 2004;233:234-240.
- Kim JY, Lee JM, Han JK, Kim SH, Lee JY, Choi JY, et al. Contrast-enhanced MRI combined with MR cholangiopancreatography for the evaluation of patients with biliary strictures: differentiation of malignant from benign bile duct strictures. J Magn Reson Imaging 2007;26:304-312.
- Wang GX, Ge XD, Zhang D, Chen HL, Zhang QC, Wen L. MRCP Combined with CT promotes the differentiation of benign and malignant distal bile duct strictures. Front Oncol 2021;11:683869.
- Mittal PK, Moreno CC, Kalb B, Mittal A, Camacho JC, Maddu K, et al. Primary biliary tract malignancies: MRI spectrum and mimics with histopathological correlation. Abdom Imaging 2015;40:1520-1557.
- Deoliveira ML, Schulick RD, Nimura Y, Rosen C, Gores G, Neuhaus P, et al. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology 2011;53:1363-1371.
- Akamatsu N, Sugawara Y, Hashimoto D. Surgical strategy for bile duct cancer: advances and current limitations. World J Clin Oncol 2011;2:94-107.
- Lee DH, Kim B, Lee ES, Kim HJ, Min JH, Lee JM, et al. Radiologic evaluation and structured reporting form for extrahepatic bile duct cancer: 2019 consensus recommendations from the korean society of abdominal radiology. Korean J Radiol 2021;22:41-62.
- Ito K, Sakamoto Y, Isayama H, Nakai Y, Watadani T, Tanaka M, et al. The impact of MDCT and endoscopic transpapillary mapping biopsy to predict longitudinal spread of extrahepatic cholangiocarcinoma. J Gastrointest Surg 2018;22:1528-1537.
- Lee HY, Kim SH, Lee JM, Kim SW, Jang JY, Han JK, et al. Preoperative assessment of resectability of hepatic hilar cholangiocarcinoma: combined CT and cholangiography with revised criteria. Radiology 2006;239:113-121.
- Unno M, Okumoto T, Katayose Y, Rikiyama T, Sato A, Motoi F, et al. Preoperative assessment of hilar cholangiocarcinoma by multidetector row computed tomography. J Hepatobiliary Pancreat Surg 2007;14:434-440.
- Masselli G, Manfredi R, Vecchioli A, Gualdi G. MR imaging and MR cholangiopancreatography in the preoperative evaluation of hilar cholangiocarcinoma: correlation with surgical and pathologic findings. Eur Radiol 2008;18:2213-2221.
- Joo I, Lee JM, Yoon JH. Imaging diagnosis of intrahepatic and perihilar cholangiocarcinoma: recent advances and challenges. Radiology 2018;288:7-13.
- Wattanasatesiri T, Sirichindakul B, Klaikaew N, Chaopathomkul B. Perihilar cholangiocarcinoma: accuracy of 16-detector-row computed tomography in evaluating tumor extension and resectability. Asian Biomed 2013;7:499-507.
- Zhou Q, Guan Y, Mao L, Zhu Y, Chen J, Shi J, et al. Modification and establishment of CT criteria in preoperative assessment of portal venous invasion by hilar cholangiocarcinoma. HPB (Oxford) 2018;20:1163-1171.
- Zhou Q, Dong G, Zhu Q, Qiu Y, Mao L, Chen J, et al. Modification and comparison of CT criteria in the preoperative assessment of hepatic arterial invasion by hilar cholangiocarcinoma. Abdom Radiol (NY) 2021;46:1922-1930.
- Ryoo I, Lee JM, Chung YE, Park HS, Kim SH, Han JK, et al. Gadobutrol-enhanced, three-dimensional, dynamic MR imaging with MR cholangiography for the preoperative evaluation of bile duct cancer. Invest Radiol 2010;45:217-224.
- Sun HY, Lee JM, Park HS, Yoon JH, Baek JH, Han JK, et al. Gadoxetic acid-enhanced MRI with MR cholangiography for the preoperative evaluation of bile duct cancer. J Magn Reson Imaging 2013;38:138-147.
- Park MJ, Kim YK, Lim S, Rhim H, Lee WJ. Hilar cholangiocarcinoma: value of adding DW imaging to gadoxetic acid-enhanced MR imaging with MR cholangiopancreatography for preoperative evaluation. Radiology 2014;270:768-776.
- Xin Y, Liu Q, Zhang J, Lu J, Song X, Zhan H, et al. Hilar cholangiocarcinoma: value of high-resolution enhanced magnetic resonance imaging for preoperative evaluation. J Cancer Res Ther 2020;16:1634-1640.
- Choi JY, Lee JM, Lee JY, Kim SH, Lee MW, Han JK, et al. Assessment of hilar and extrahepatic bile duct cancer using multidetector CT: value of adding multiplanar reformations to standard axial images. Eur Radiol 2007;17:3130-3138.
- Li H, Zeng MS, Zhou KR, Jin DY, Lou WH. Pancreatic adenocarcinoma: the different CT criteria for peripancreatic major arterial and venous invasion. J Comput Assist Tomogr 2005;29:170-175.
- Lu DS, Reber HA, Krasny RM, Kadell BM, Sayre J. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol 1997;168:1439-1443.
- Mizuno T, Ebata T, Yokoyama Y, Igami T, Yamaguchi J, Onoe S, et al. Combined vascular resection for locally advanced perihilar cholangiocarcinoma. Ann Surg 2022;275:382-390.
- Songthamwat M, Chamadol N, Khuntikeo N, Thinkhamrop J, Koonmee S, Chaichaya N, et al. Accuracy of computerised tomography scan for the diagnosis of lymph node metastasis in cholangiocarcinoma. J Clin Diagn Res 2018;12:PC12-PC16.
- Ni Q, Wang H, Zhang Y, Qian L, Chi J, Liang X, et al. MDCT assessment of resectability in hilar cholangiocarcinoma. Abdom Radiol (NY) 2017;42:851-860.
- Promsorn J, Soontrapa W, Somsap K, Chamadol N, Limpawattana P, Harisinghani M. Evaluation of the diagnostic performance of apparent diffusion coefficient (ADC) values on diffusion-weighted magnetic resonance imaging (DWI) in differentiating between benign and metastatic lymph nodes in cases of cholangiocarcinoma. Abdom Radiol (NY) 2019;44:473-481.
- Wu XP, Ni JM, Zhang ZY, Lu FQ, Li B, Jin HH, et al. Preoperative evaluation of malignant perihilar biliary obstruction: negative-contrast CT cholangiopancreatography and CT angiography versus MRCP and MR angiography. AJR Am J Roentgenol 2015;205:780-788.
- Pang L, Bo X, Wang J, Wang C, Wang Y, Liu G, et al. Role of dual-time point (18)F-FDG PET/CT imaging in the primary diagnosis and staging of hilar cholangiocarcinoma. Abdom Radiol (NY) 2021;46:4138-4147.
- Lamarca A, Barriuso J, Chander A, Mcnamara MG, Hubner RA, Õreilly D, et al. (18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis. J Hepatol 2019;71:115-129.
- Hu JH, Tang JH, Lin CH, Chu YY, Liu NJ. Preoperative staging of cholangiocarcinoma and biliary carcinoma using 18F-fluorodeoxyglucose positron emission tomography: a meta-analysis. J Investig Med 2018;66:52-61.
- Kim JY, Kim MH, Lee TY, Hwang CY, Kim JS, Yun SC, et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol 2008;103:1145-1151.
- Huang X, Yang J, Li J, Xiong Y. Comparison of magnetic resonance imaging and 18-fludeoxyglucose positron emission tomography/computed tomography in the diagnostic accuracy of staging in patients with cholangiocarcinoma: a meta-analysis. Medicine (Baltimore) 2020;99:e20932.
- Noji T, Kondo S, Hirano S, Tanaka E, Suzuki O, Shichinohe T. Computed tomography evaluation of regional lymph node metastases in patients with biliary cancer. Br J Surg 2008;95:92-96.
- Barlow AD, Garcea G, Berry DP, Rajesh A, Patel R, Metcalfe MS, et al. Staging laparoscopy for hilar cholangiocarcinoma in 100 patients. Langenbecks Arch Surg 2013;398:983-988.
- Aloia TA, Charnsangavej C, Faria S, Ribero D, Abdalla EK, Vauthey JN, et al. High-resolution computed tomography accurately predicts resectability in hilar cholangiocarcinoma. Am J Surg 2007;193:702-706.
- Zhang H, Zhu J, Ke F, Weng M, Wu X, Li M, et al. Radiological imaging for assessing the respectability of hilar cholangiocarcinoma: a systematic review and meta-analysis. Biomed Res Int 2015;2015:497942.
- Choi SY, Kim YK, Min JH, Cha DI, Jeong WK, Lee WJ. The value of gadoxetic acid-enhanced MRI for differentiation between hepatic microabscesses and metastases in patients with periampullary cancer. Eur Radiol 2017;27:4383-4393.
- Bridgewater J, Lopes A, Beare S, Duggan M, Lee D, Ricamara M, et al. A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC04 study. BMC Cancer 2016;16:153.
- Chiang NJ, Chen JS, Chen MH, Yang SH, Hsu C, Yen CJ, et al. A phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer. J Clin Oncol 2017;35:417.
- Coombs RJ, Zeiss J, Howard JM, Thomford NR, Merrick HW. CT of the abdomen after the Whipple procedure: value in depicting postoperative anatomy, surgical complications, and tumor recurrence. AJR Am J Roentgenol 1990;154:1011-1014.
- Manzione L, Romano R, Germano D. Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience. Oncology 2007;73:311-315.
- Pongmaneratanakul S, Tanasanvimon S, Pengsuparp T, Areepium N. Prevalence of CTR1 and ERCC1 polymorphisms and response of biliary tract cancer to gemcitabine-platinum chemotherapy. Asian Pac J Cancer Prev 2017;18:857-861.
- Sahani DV, Hayano K, Galluzzo A, Zhu AX. Measuring treatment response to systemic therapy and predicting outcome in biliary tract cancer: comparing tumor size, volume, density, and metabolism. AJR Am J Roentgenol 2015;204:776-781.
- Wang D, Yang X, Long J, Lin J, Mao J, Xie F, et al. the efficacy and safety of apatinib plus camrelizumab in patients with previously treated advanced biliary tract cancer: a prospective clinical study. Front Oncol 2021;11:646979.
- Jung SJ, Woo SM, Park HK, Lee WJ, Han MA, Han SS, et al. Patterns of initial disease recurrence after resection of biliary tract cancer. Oncology 2012;83:83-90.
- Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:v28-v37.
- Kim NH, Lee SR, Kim YH, Kim HJ. Diagnostic performance and prognostic relevance of FDG positron emission tomography/computed tomography for patients with extrahepatic cholangiocarcinoma. Korean J Radiol 2020;21:1355-1366.
- Petrowsky H, Wildbrett P, Husarik DB, Hany TF, Tam S, Jochum W, et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006;45:43-50.
- Kato T, Tsukamoto E, Kuge Y, Katoh C, Nambu T, Nobuta A, et al. Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging 2002;29:1047-1054.
- Albazaz R, Patel CN, Chowdhury FU, Scarsbrook AF. Clinical impact of FDG PET-CT on management decisions for patients with primary biliary tumours. Insights Imaging 2013;4:691-700.
- Corvera CU, Blumgart LH, Akhurst T, Dematteo RP, D'Angelica M, Fong Y, et al. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 2008;206:57-65.
- Tashiro S, Imaizumi T, Ohkawa H, Okada A, Katoh T, Kawaharada Y, et al. Pancreaticobiliary maljunction: retrospective and nationwide survey in Japan. J Hepatobiliary Pancreat Surg 2003;10:345-351.
- Tsuchida A, Itoi T, Endo M, Kitamura K, Mukaide M, Itokawa F, et al. Pathological features and surgical outcome of pancreaticobiliary maljunction without dilatation of the extrahepatic bile duct. Oncol Rep 2004;11:269-276.
- Yu ZL, Zhang LJ, Fu JZ, Li J, Zhang QY, Chen FL. Anomalous pancreaticobiliary junction: image analysis and treatment principles. Hepatobiliary Pancreat Dis Int 2004;3:136-139.
- Jung YS, Lee KJ, Kim H, Kim WH, Kim IG, Yoo BM, et al. Risk factor for extrahepatic bile duct cancer in patients with anomalous pancreaticobiliary ductal union. Hepatogastroenterology 2004;51:946-949.
- Ohuchida J, Chijiiwa K, Hiyoshi M, Kobayashi K, Konomi H, Tanaka M. Long-term results of treatment for pancreaticobiliary maljunction without bile duct dilatation. Arch Surg 2006;141:1066-1070.
- Takuma K, Kamisawa T, Tabata T, Hara S, Kuruma S, Inaba Y, et al. Importance of early diagnosis of pancreaticobiliary maljunction without biliary dilatation. World J Gastroenterol 2012;18:3409-3414.
- Morine Y, Shimada M, Takamatsu H, Araida T, Endo I, Kubota M, et al. Clinical features of pancreaticobiliary maljunction: update analysis of 2nd Japan-nationwide survey. J Hepatobiliary Pancreat Sci 2013;20:472-480.
- Hayashi H, Beppu T, Okabe H, Kuroki H, Nakagawa S, Imai K, et al. Functional assessment versus conventional volumetric assessment in the prediction of operative outcomes after major hepatectomy. Surgery 2015;157:20-26.
- Olthof PB, Wiggers JK, Groot Koerkamp B, Coelen RJ, Allen PJ, Besselink MG, et al. Postoperative liver failure risk score: identifying patients with resectable perihilar cholangiocarcinoma who can benefit from portal vein embolization. J Am Coll Surg 2017;225:387-394.
- Olthof PB, Coelen RJS, Bennink RJ, Heger M, Lam MF, Besselink MG, et al. (99m)Tc-mebrofenin hepatobiliary scintigraphy predicts liver failure following major liver resection for perihilar cholangiocarcinoma. HPB (Oxford) 2017;19:850-858.
- Yokoyama Y, Ebata T, Igami T, Sugawara G, Mizuno T, Yamaguchi J, et al. The predictive value of indocyanine green clearance in future liver remnant for posthepatectomy liver failure following hepatectomy with extrahepatic bile duct resection. World J Surg 2016;40:1440-1447.
- Kuboki S, Furukawa K, Takayashiki T, Takano S, Miyazaki M, Ohtsuka M. Clinical implication of ICG test in major hepatectomy for biliary tract cancer. Minerva Surg 2021;76:202-210.
- Franken LC, Rassam F, Van Lienden KP, Bennink RJ, Besselink MG, Busch OR, et al. Effect of structured use of preoperative portal vein embolization on outcomes after liver resection of perihilar cholangiocarcinoma. BJS Open 2020;4:449-455.
- Higuchi R, Yamamoto M. Indications for portal vein embolization in perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2014;21:542-549.
- Konishi T, Takamoto T, Hashimoto T, Makuuchi M. Is portal vein embolization safe and effective for patients with impaired liver function? J Surg Oncol 2021;123:1742-1749.
- Olthof PB, Aldrighetti L, Alikhanov R, Cescon M, Groot Koerkamp B, Jarnagin WR, et al. Portal vein embolization is associated with reduced liver failure and mortality in high-risk resections for perihilar cholangiocarcinoma. Ann Surg Oncol 2020;27:2311-2318.
- Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003;237:208-217.
- Hong YK, Choi SB, Lee KH, Park SW, Park YN, Choi JS, et al. The efficacy of portal vein embolization prior to right extended hemihepatectomy for hilar cholangiocellular carcinoma: a retrospective cohort study. Eur J Surg Oncol 2011;37:237-244.
- Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002;137:675-680; discussion 680-671.
- Gazzaniga GM, Filauro M, Bagarolo C, Mori L. Surgery for hilar cholangiocarcinoma: an Italian experience. J Hepatobiliary Pancreat Surg 2000;7:122-127.
- Cho MS, Kim SH, Park SW, Lim JH, Choi GH, Park JS, et al. Surgical outcomes and predicting factors of curative resection in patients with hilar cholangiocarcinoma: 10-year single-institution experience. J Gastrointest Surg 2012;16:1672-1679.
- Kow AW, Wook CD, Song SC, Kim WS, Kim MJ, Park HJ, et al. Role of caudate lobectomy in type III A and III B hilar cholangiocarcinoma: a 15-year experience in a tertiary institution. World J Surg 2012;36:1112-1121.
- Wahab MA, Sultan AM, Salah T, Fathy O, Elebidy G, Elshobary M, et al. Caudate lobe resection with major hepatectomy for central cholangiocarcinoma: is it of value? Hepatogastroenterology 2012;59:321-324.
- Cheng QB, Yi B, Wang JH, Jiang XQ, Luo XJ, Liu C, et al. Resection with total caudate lobectomy confers survival benefit in hilar cholangiocarcinoma of Bismuth type III and IV. Eur J Surg Oncol 2012;38:1197-1203.
- Abd Elwahab M, El Nakeeb A, El Hanafy E, Sultan AM, Elghawalby A, Askr W, et al. Predictors of long term survival after hepatic resection for hilar cholangiocarcinoma: A retrospective study of 5-year survivors. World J Gastrointest Surg 2016;8:436-443.
- Bhutiani N, Scoggins CR, Mcmasters KM, Ethun CG, Poultsides GA, Pawlik TM, et al. The impact of caudate lobe resection on margin status and outcomes in patients with hilar cholangiocarcinoma: a multi-institutional analysis from the US Extrahepatic Biliary Malignancy Consortium. Surgery 2018;163:726-731.
- Geers J, Jaekers J, Topal H, Aerts R, Vandoren C, Vanden Boer G, et al. Predictors of survival after surgery with curative intent for perihilar cholangiocarcinoma. World J Surg Oncol 2020;18:286.
- Birgin E, Rasbach E, Reissfelder C, Rahbari NN. A systematic review and meta-analysis of caudate lobectomy for treatment of hilar cholangiocarcinoma. Eur J Surg Oncol 2020;46:747-753.
- Yang M, Li WW, Chen JH, Cui MH, Liu JL. The value of caudate lobectomy in hilar cholangiocarcinoma treatment: a meta-analysis. Medicine (Baltimore) 2021;100:e24727.
- Kitagawa Y, Nagino M, Kamiya J, Uesaka K, Sano T, Yamamoto H, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg 2001;233:385-392.
- Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, et al. Is para-aortic lymph node metastasis a contraindication for radical resection in biliary carcinoma? World J Surg 2011;35:1085-1093.
- Hakeem AR, Marangoni G, Chapman SJ, Young RS, Nair A, Hidalgo EL, et al. Does the extent of lymphadenectomy, number of lymph nodes, positive lymph node ratio and neutrophil-lymphocyte ratio impact surgical outcome of perihilar cholangiocarcinoma? Eur J Gastroenterol Hepatol 2014;26:1047-1054.
- De Jong MC, Marques H, Clary BM, Bauer TW, Marsh JW, Ribero D, et al. The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases. Cancer 2012;118:4737-4747.
- Dumitrascu T, Stroescu C, Brasoveanu V, Herlea V, Ionescu M, Popescu I. Curative-intent Surgery for Perihilar Cholangiocarcinoma with and without Portal Vein Resection - a Comparative Analysis of Early and Late Outcomes. Chirurgia (Bucur) 2017;112:308-319.
- Hoffmann K, Luible S, Goeppert B, Weiss KH, Hinz U, Buchler MW, et al. Impact of portal vein resection on oncologic long-term outcome in patients with hilar cholangiocarcinoma. Surgery 2015;158:1252-1260.
- Matsuyama R, Mori R, Ota Y, Homma Y, Kumamoto T, Takeda K, et al. Significance of vascular resection and reconstruction in surgery for hilar cholangiocarcinoma: with special reference to hepatic arterial resection and reconstruction. Ann Surg Oncol 2016;23:475-484.
- Song GW, Lee SG, Hwang S, Kim KH, Cho YP, Ahn CS, et al. Does portal vein resection with hepatectomy improve survival in locally advanced hilar cholangiocarcinoma? Hepatogastroenterology 2009;56:935-942.
- Wang ST, Shen SL, Peng BG, Hua YP, Chen B, Kuang M, et al. Combined vascular resection and analysis of prognostic factors for hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2015;14:626-632.
- Tamoto E, Hirano S, Tsuchikawa T, Tanaka E, Miyamoto M, Matsumoto J, et al. Portal vein resection using the no-touch technique with a hepatectomy for hilar cholangiocarcinoma. HPB (Oxford) 2014;16:56-61.
- She WH, Cheung TT, Ma KW, Tsang SHY, Dai WC, Chan ACY, et al. Vascular resection and reconstruction in hilar cholangiocarcinoma. ANZ J Surg 2020;90:1653-1659.
- Liu Y, Li G, Lu Z, Wang T, Yang Y, Wang X, et al. Effect of vascular resection for perihilar cholangiocarcinoma: a systematic review and meta-analysis. PeerJ 2021;9:e12184.
- Lurje G, Bednarsch J, Czigany Z, Lurje I, Schlebusch IK, Boecker J, et al. The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma. Eur J Surg Oncol 2019;45:1468-1478.
- Nagino M, Nimura Y, Nishio H, Ebata T, Igami T, Matsushita M, et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases. Ann Surg 2010;252:115-123.
- Ebata T, Nagino M, Kamiya J, Uesaka K, Nagasaka T, Nimura Y. Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann Surg 2003;238:720-727.
- Schimizzi GV, Jin LX, Davidson JTT, Krasnick BA, Ethun CG, Pawlik TM, et al. Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford) 2018;20:332-339.
- Yamaguchi K, Shirahane K, Nakamura M, Su D, Konomi H, Motoyama K, et al. Frozen section and permanent diagnoses of the bile duct margin in gallbladder and bile duct cancer. HPB (Oxford) 2005;7:135-138.
- Otsuka S, Ebata T, Yokoyama Y, Mizuno T, Tsukahara T, Shimoyama Y, et al. Clinical value of additional resection of a margin-positive distal bile duct in perihilar cholangiocarcinoma. Br J Surg 2019;106:774-782.
- Yasukawa K, Shimizu A, Motoyama H, Kubota K, Notake T, Fukushima K, et al. Impact of remnant carcinoma in situ at the ductal stump on long-term outcomes in patients with distal cholangiocarcinoma. World J Surg 2021;45:291-301.
- Park Y, Hwang DW, Kim JH, Hong SM, Jun SY, Lee JH, et al. Prognostic comparison of the longitudinal margin status in distal bile duct cancer: R0 on first bile duct resection versus R0 after additional resection. J Hepatobiliary Pancreat Sci 2019;26:169-178.
- Yoo T, Park SJ, Han SS, Kim SH, Lee SD, Kim TH, et al. Proximal resection margins: more prognostic than distal resection margins in patients undergoing hilar cholangiocarcinoma resection. Cancer Res Treat 2018;50:1106-1113.
- Lee JH, Hwang DW, Lee SY, Park KM, Lee YJ. The proximal margin of resected hilar cholangiocarcinoma: the effect of microscopic positive margin on long-term survival. Am Surg 2012;78:471-477.
- Shin D, Lee S, Lee JH, Hong SM, Park SY, Yoo C, et al. Prognostic implication of high grade biliary intraepithelial neoplasia in bile duct resection margins in patients with resected perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2020;27:604-613.
- Nakanishi Y, Kondo S, Zen Y, Yonemori A, Kubota K, Kawakami H, et al. Impact of residual in situ carcinoma on postoperative survival in 125 patients with extrahepatic bile duct carcinoma. J Hepatobiliary Pancreat Sci 2010;17:166-173.
- Sasaki R, Takeda Y, Funato O, Nitta H, Kawamura H, Uesugi N, et al. Significance of ductal margin status in patients undergoing surgical resection for extrahepatic cholangiocarcinoma. World J Surg 2007;31:1788-1796.
- Wakai T, Shirai Y, Moroda T, Yokoyama N, Hatakeyama K. Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. Cancer 2005;103:1210-1216.
- Tsukahara T, Ebata T, Shimoyama Y, Yokoyama Y, Igami T, Sugawara G, et al. Residual carcinoma in situ at the ductal stump has a negative survival effect: an analysis of early-stage cholangiocarcinomas. Ann Surg 2017;266:126-132.
- Han IW, Jang JY, Lee KB, Kang MJ, Kwon W, Park JW, et al. Clinicopathological analysis and prognosis of extrahepatic bile duct cancer with a microscopic positive ductal margin. HPB (Oxford) 2014;16:575-581.
- Higuchi R, Ota T, Araida T, Kobayashi M, Furukawa T, Yamamoto M. Prognostic relevance of ductal margins in operative resection of bile duct cancer. Surgery 2010;148:7-14.
- Kurahara H, Maemura K, Mataki Y, Sakoda M, Iino S, Kawasaki Y, et al. Relationship between the surgical margin status, prognosis, and recurrence in extrahepatic bile duct cancer patients. Langenbecks Arch Surg 2017;402:87-93.
- Higuchi R, Yazawa T, Uemura S, Izumo W, Furukawa T, Yamamoto M. High-grade dysplasia/carcinoma in situ of the bile duct margin in patients with surgically resected node-negative perihilar cholangiocarcinoma is associated with poor survival: a retrospective study. J Hepatobiliary Pancreat Sci 2017;24:456-465.
- Wakai T, Shirai Y, Tsuchiya Y, Nomura T, Akazawa K, Hatakeyama K. Combined major hepatectomy and pancreaticoduodenectomy for locally advanced biliary carcinoma: long-term results. World J Surg 2008;32:1067-1074.
- Fukami Y, Kaneoka Y, Maeda A, Takayama Y, Onoe S. Major heaptopancreatoduodenectomy with simultaneous resection of the hepatic artery for advanced biliary cancer. Langenbecks Arch Surg 2016;401:471-478.
- Sakamoto Y, Nara S, Kishi Y, Esaki M, Shimada K, Kokudo N, et al. Is extended hemihepatectomy plus pancreaticoduodenectomy justified for advanced bile duct cancer and gallbladder cancer? Surgery 2013;153:794-800.
- Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, Nimura Y, et al. Hepatopancreatoduodenectomy for cholangiocarcinoma: a single-center review of 85 consecutive patients. Ann Surg 2012;256:297-305.
- Shimizu A, Motoyama H, Kubota K, Notake T, Fukushima K, Ikehara T, et al. Safety and oncological benefit of hepatopancreatoduodenectomy for advanced extrahepatic cholangiocarcinoma with horizontal tumor spread: shinshu university experience. Ann Surg Oncol 2021;28:2012-2025.
- Wang S, Shi N, You L, Dai M, Zhao Y. Minimally invasive surgical approach versus open procedure for pancreaticoduodenectomy: a systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e8619.
- Kim SH, Lee B, Hwang HK, Lee JS, Han HS, Lee WJ, et al. Comparison of postoperative complications and long-term oncological outcomes in minimally invasive versus open pancreatoduodenectomy for distal cholangiocarcinoma: a propensity score-matched analysis. J Hepatobiliary Pancreat Sci 2022;29:329-337.
- Nickel F, Haney CM, Kowalewski KF, Probst P, Limen EF, Kalkum E, et al. Laparoscopic versus open pancreaticoduodenectomy: a systematic review and meta-analysis of randomized controlled trials. Ann Surg 2020;271:54-66.
- Kamarajah SK, Gujjuri R, Bundred JR, Hilal MA, White SA. Longterm survival after minimally invasive resection versus open pancreaticoduodenectomy for periampullary cancers: a systematic review, meta-analysis and meta-regression. HPB (Oxford) 2021;23:197-205.
- Ma D, Wang W, Wang J, Zhang T, Jiang Z, Du G, et al. Laparoscopic versus open surgery for hilar cholangiocarcinoma: a retrospective cohort study on short-term and long-term outcomes. Surg Endosc 2022;36:3721-3731.
- Delitto D, Luckhurst CM, Black BS, Beck JL, George TJ, Jr., Sarosi GA, et al. Oncologic and perioperative outcomes following selective application of laparoscopic pancreaticoduodenectomy for periampullary malignancies. J Gastrointest Surg 2016;20:1343-1349.
- Li J, Xiong Y, Yang G, Zhang L, Riaz M, Xu J, et al. Complete laparoscopic radical resection of hilar cholangiocarcinoma: technical aspects and long-term results from a single center. Wideochir Inne Tech Maloinwazyjne 2021;16:62-75.
- Jingdong L, Yongfu X, Yang G, Jian X, Xujian H, Jianhua L, et al. Minimally invasive surgery for hilar cholangiocarcinoma: a multicenter retrospective analysis of 158 patients. Surg Endosc 2021;35:6612-6622.
- Zhang Y, Dou C, Wu W, Liu J, Jin L, Hu Z, et al. Total laparoscopic versus open radical resection for hilar cholangiocarcinoma. Surg Endosc 2020;34:4382-4387.
- Li J, Tan X, Zhang X, Zhao G, Hu M, Zhao Z, et al. Robotic radical surgery for hilar cholangiocarcinoma: a single-centre case series. Int J Med Robot 2020;16:e2076.
- Feng F, Cao X, Liu X, Qin J, Zhang S, Li Q, et al. Laparoscopic resection for Bismuth type III and IV hilar cholangiocarcinoma: how to improve the radicality without direct palpation. J Surg Oncol 2019;120:1379-1385.
- Li J, Zhao L, Zhang J, Li Z, Li A, Wei Y, et al. Application of the laparoscopic technique in perihilar cholangiocarcinoma surgery. Int J Surg 2017;44:104-109.
- Xu Y, Wang H, Ji W, Tang M, Li H, Leng J, et al. Robotic radical resection for hilar cholangiocarcinoma: perioperative and long-term outcomes of an initial series. Surg Endosc 2016;30:3060-3070.
- Yu H, Wu SD, Chen DX, Zhu G. Laparoscopic resection of Bismuth type I and II hilar cholangiocarcinoma: an audit of 14 cases from two institutions. Dig Surg 2011;28:44-49.
- Lee GI, Lee MR, Green I, Allaf M, Marohn MR. Surgeons' physical discomfort and symptoms during robotic surgery: a comprehensive ergonomic survey study. Surg Endosc 2017;31:1697-1706.
- Deoliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007;245:755-762.
- Aoba T, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, et al. Assessment of nodal status for perihilar cholangiocarcinoma: location, number, or ratio of involved nodes. Ann Surg 2013;257:718-725.
- Shiraki T, Kuroda H, Takada A, Nakazato Y, Kubota K, Imai Y. Intraoperative frozen section diagnosis of bile duct margin for extrahepatic cholangiocarcinoma. World J Gastroenterol 2018;24:1332-1342.
- Endo I, House MG, Klimstra DS, Gonen M, D'Angelica M, Dematteo RP, et al. Clinical significance of intraoperative bile duct margin assessment for hilar cholangiocarcinoma. Ann Surg Oncol 2008;15:2104-2112.
- Zhang XF, Squires MH, 3rd, Bagante F, Ethun CG, Salem A, Weber SM, et al. The impact of intraoperative re-resection of a positive bile duct margin on clinical outcomes for hilar cholangiocarcinoma. Ann Surg Oncol 2018;25:1140-1149.
- American Joint Committee on Cancer. AJCC Cancer Staging Manual. 8th ed.: Springer Cham, 2017.
- Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, Mcdonald AC, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. Jama 2012;308:147-156.
- Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol 2019;37:658-667.
- Ebata T, Hirano S, Konishi M, Uesaka K, Tsuchiya Y, Ohtsuka M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg 2018;105:192-202.
- Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 2019;20:663-673.
- Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-1281.
- Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022;1:EVIDoa2200015.
- Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet 2023;401:1853-1865.
- Gwak HK, Kim WC, Kim HJ, Park JH. Extrahepatic bile duct cancers: surgery alone versus surgery plus postoperative radiation therapy. Int J Radiat Oncol Biol Phys 2010;78:194-198.
- Chang WI, Kim BH, Kang HC, Kim K, Lee KH, Oh DY, et al. The role of adjuvant chemoradiotherapy in nonhilar extrahepatic bile duct cancer: a long-term single-institution analysis. Int J Radiat Oncol Biol Phys 2021;111:395-404.
- Todoroki T, Ohara K, Kawamoto T, Koike N, Yoshida S, Kashiwagi H, et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys 2000;46:581-587.
- Kobayashi S, Nagano H, Marubashi S, Takeda Y, Tanemura M, Konishi K, et al. Impact of postoperative irradiation after non-curative resection of hilar biliary cancer. J Surg Oncol 2009;100:657-662.
- Hoehn RS, Wima K, Ertel AE, Meier A, Ahmad SA, Shah SA, et al. Adjuvant chemotherapy and radiation therapy is associated with improved survival for patients with extrahepatic cholangiocarcinoma. Ann Surg Oncol 2015;22 Suppl 3:S1133-1139.
- Nassour I, Mokdad AA, Porembka MR, Choti MA, Polanco PM, Mansour JC, et al. Adjuvant therapy is associated with improved survival in resected perihilar cholangiocarcinoma: a propensity matched study. Ann Surg Oncol 2018;25:1193-1201.
- Kamarajah SK, Bednar F, Cho CS, Nathan H. Survival benefit with adjuvant radiotherapy after resection of distal cholangiocarcinoma: a propensity-matched National Cancer Database analysis. Cancer 2021;127:1266-1274.
- Kim K, Yu JI, Jung W, Kim TH, Seong J, Kim WC, et al. Role of adjuvant radiotherapy in extrahepatic bile duct cancer: a multicenter retrospective study (Korean Radiation Oncology Group 18-14). Eur J Cancer 2021;157:31-39.
- Bonet Beltran M, Allal AS, Gich I, Sole JM, Carrio I. Is adjuvant radiotherapy needed after curative resection of extrahepatic biliary tract cancers? A systematic review with a meta-analysis of observational studies. Cancer Treat Rev 2012;38:111-119.
- Shi XQ, Zhang JY, Tian H, Tang LN, Li AL. Role of adjuvant (chemo) radiotherapy for resected extrahepatic cholangiocarcinoma: a meta-analysis. J Zhejiang Univ Sci B 2020;21:549-559.
- Choi SH, Rim CH, Shin IS, Yoon WS, Koom WS, Seong J. Adjuvant radiotherapy for extrahepatic cholangiocarcinoma: a quality assessment-based meta-analysis. Liver Cancer 2021;10:419-432.
- Bowling TE, Galbraith SM, Hatfield AR, Solano J, Spittle MF. A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. Gut 1996;39:852-855.
- Valek V, Kysela P, Kala Z, Kiss I, Tomasek J, Petera J. Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma: a prospective randomised study. Eur J Radiol 2007;62:175-179.
- Jiao D, Wu G, Ren J, Han X. Study of self-expandable metallic stent placement intraluminal (125)I seed strands brachytherapy of malignant biliary obstruction. Surg Endosc 2017;31:4996-5005.
- De Bellis M, Fogel EL, Sherman S, Watkins JL, Chappo J, Younger C, et al. Influence of stricture dilation and repeat brushing on the cancer detection rate of brush cytology in the evaluation of malignant biliary obstruction. Gastrointest Endosc 2003;58:176-182.
- Pugliese V, Conio M, Nicolo G, Saccomanno S, Gatteschi B. Endoscopic retrograde forceps biopsy and brush cytology of biliary strictures: a prospective study. Gastrointest Endosc 1995;42:520-526.
- Yasuda I, Enya M, Moriwaki H, Tomita E, Kato T, Mukai T, et al. Diagnostic value of transpapillary biopsy using double lumen introducer for determination of mucosal extent in extrahepatic bile duct cancer. Dig Endosc 2003;15:200-205.
- Mansfield JC, Griffin SM, Wadehra V, Matthewson K. A prospective evaluation of cytology from biliary strictures. Gut 1997;40:671-677.
- Fogel EL, Debellis M, Mchenry L, Watkins JL, Chappo J, Cramer H, et al. Effectiveness of a new long cytology brush in the evaluation of malignant biliary obstruction: a prospective study. Gastrointest Endosc 2006;63:71-77.
- Bang JY, Navaneethan U, Hasan M, Sutton B, Hawes R, Varadarajulu S. Optimizing outcomes of single-operator cholangioscopy-guided biopsies based on a randomized trial. Clin Gastroenterol Hepatol 2020;18:441-448.e441.
- Fritscher-Ravens A, Broering DC, Sriram PV, Topalidis T, Jaeckle S, Thonke F, et al. EUS-guided fine-needle aspiration cytodiagnosis of hilar cholangiocarcinoma: a case series. Gastrointest Endosc 2000;52:534-540.
- Tsai CC, Mo LR, Chou CY, Han SJ, Lin RC, Kuo JY, et al. Percutaneous transhepatic transluminal forceps biopsy in obstructive jaundice. Hepatogastroenterology 1997;44:770-773.
- Moon JH, Terheggen G, Choi HJ, Neuhaus H. Peroral cholangioscopy: diagnostic and therapeutic applications. Gastroenterology 2013;144:276-282.
- Asge Technology Committee; Komanduri S, Thosani N, Abu Dayyeh BK, Aslanian HR, Enestvedt BK, Manfredi M, et al. Cholangiopancreatoscopy. Gastrointest Endosc 2016;84:209-221.
- Manta R, Frazzoni M, Conigliaro R, Maccio L, Melotti G, Dabizzi E, et al. SpyGlass single-operator peroral cholangioscopy in the evaluation of indeterminate biliary lesions: a single-center, prospective, cohort study. Surg Endosc 2013;27:1569-1572.
- Siddiqui AA, Mehendiratta V, Jackson W, Loren DE, Kowalski TE, Eloubeidi MA. Identification of cholangiocarcinoma by using the Spyglass Spyscope system for peroral cholangioscopy and biopsy collection. Clin Gastroenterol Hepatol 2012;10:466-471; quiz e448.
- Ramchandani M, Reddy DN, Gupta R, Lakhtakia S, Tandan M, Darisetty S, et al. Role of single-operator peroral cholangioscopy in the diagnosis of indeterminate biliary lesions: a single-center, prospective study. Gastrointest Endosc 2011;74:511-519.
- Draganov PV, Chauhan S, Wagh MS, Gupte AR, Lin T, Hou W, et al. Diagnostic accuracy of conventional and cholangioscopy-guided sampling of indeterminate biliary lesions at the time of ERCP: a prospective, long-term follow-up study. Gastrointest Endosc 2012;75:347-353.
- Lee YN, Moon JH, Choi HJ, Kim HK, Lee HW, Lee TH, et al. Tissue acquisition for diagnosis of biliary strictures using peroral cholangioscopy or endoscopic ultrasound-guided fine-needle aspiration. Endoscopy 2019;51:50-59.
- Hattori M, Nagino M, Ebata T, Kato K, Okada K, Shimoyama Y. Prospective study of biliary cytology in suspected perihilar cholangiocarcinoma. Br J Surg 2011;98:704-709.
- Tsuchiya T, Yokoyama Y, Ebata T, Igami T, Sugawara G, Kato K, et al. Randomized controlled trial on timing and number of sampling for bile aspiration cytology. J Hepatobiliary Pancreat Sci 2014;21:433-438.
- Kylanpaa L, Boyd S, Ristimaki A, Lindstrom O, Udd M, Halttunen J. A prospective randomised study of dense Infinity cytological brush versus regularly used brush in pancreaticobiliary malignancy. Scand J Gastroenterol 2016;51:590-593.
- Abraham NS, Barkun JS, Barkun AN. Palliation of malignant biliary obstruction: a prospective trial examining impact on quality of life. Gastrointest Endosc 2002;56:835-841.
- Williamsson C, Wennerblom J, Tingstedt B, Jonsson C. A wait-and-see strategy with subsequent self-expanding metal stent on demand is superior to prophylactic bypass surgery for unresectable periampullary cancer. HPB (Oxford) 2016;18:107-112.
- Smith AC, Dowsett JF, Russell RC, Hatfield AR, Cotton PB. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 1994;344:1655-1660.
- Leng JJ, Zhang N, Dong JH. Percutaneous transhepatic and endoscopic biliary drainage for malignant biliary tract obstruction: a meta-analysis. World J Surg Oncol 2014;12:272.
- Zhao XQ, Dong JH, Jiang K, Huang XQ, Zhang WZ. Comparison of percutaneous transhepatic biliary drainage and endoscopic biliary drainage in the management of malignant biliary tract obstruction: a meta-analysis. Dig Endosc 2015;27:137-145.
- Almadi MA, Barkun A, Martel M. Plastic vs. self-expandable metal stents for palliation in malignant biliary obstruction: a series of meta-analyses. Am J Gastroenterol 2017;112:260-273.
- Davids PH, Groen AK, Rauws EA, Tytgat GN, Huibregtse K. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet 1992;340:1488-1492.
- Lammer J, Hausegger KA, Fluckiger F, Winkelbauer FW, Wildling R, Klein GE, et al. Common bile duct obstruction due to malignancy: treatment with plastic versus metal stents. Radiology 1996;201:167-172.
- Soderlund C, Linder S. Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial. Gastrointest Endosc 2006;63:986-995.
- Isayama H, Komatsu Y, Tsujino T, Sasahira N, Hirano K, Toda N, et al. A prospective randomised study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction. Gut 2004;53:729-734.
- Almadi MA, Barkun AN, Martel M. No benefit of covered vs uncovered self-expandable metal stents in patients with malignant distal biliary obstruction: a meta-analysis. Clin Gastroenterol Hepatol 2013;11:27-37.e21.
- Krokidis M, Fanelli F, Orgera G, Bezzi M, Passariello R, Hatzidakis A. Percutaneous treatment of malignant jaundice due to extrahepatic cholangiocarcinoma: covered Viabil stent versus uncovered Wallstents. Cardiovasc Intervent Radiol 2010;33:97-106.
- Telford JJ, Carr-Locke DL, Baron TH, Poneros JM, Bounds BC, Kelsey PB, et al. A randomized trial comparing uncovered and partially covered self-expandable metal stents in the palliation of distal malignant biliary obstruction. Gastrointest Endosc 2010;72:907-914.
- Kullman E, Frozanpor F, Soderlund C, Linder S, Sandstrom P, Lindhoff-Larsson A, et al. Covered versus uncovered self-expandable nitinol stents in the palliative treatment of malignant distal biliary obstruction: results from a randomized, multicenter study. Gastrointest Endosc 2010;72:915-923.
- Saleem A, Leggett CL, Murad MH, Baron TH. Meta-analysis of randomized trials comparing the patency of covered and uncovered self-expandable metal stents for palliation of distal malignant bile duct obstruction. Gastrointest Endosc 2011;74:321-327.e321-323.
- Kawashima H, Hashimoto S, Ohno E, Ishikawa T, Morishima T, Matsubara H, et al. Comparison of 8- and 10-mm diameter fully covered self-expandable metal stents: a multicenter prospective study in patients with distal malignant biliary obstruction. Dig Endosc 2019;31:439-447.
- Lee YN, Moon JH, Choi HJ, Choi MH, Lee TH, Cha SW, et al. Effectiveness of a newly designed antireflux valve metal stent to reduce duodenobiliary reflux in patients with unresectable distal malignant biliary obstruction: a randomized, controlled pilot study (with videos). Gastrointest Endosc 2016;83:404-412.
- Hamada T, Nakai Y, Isayama H. Two meta-analyses with different conclusions: stent outcomes should be standardized before their integration. Clin Gastroenterol Hepatol 2013;11:748.
- Isayama H, Hamada T, Yasuda I, Itoi T, Ryozawa S, Nakai Y, et al. TOKYO criteria 2014 for transpapillary biliary stenting. Dig Endosc 2015;27:259-264.
- De Cassan C, Bories E, Pesenti C, Caillol F, Godat S, Ratone JP, et al. Use of partially covered and uncovered metallic prosthesis for endoscopic ultrasound-guided hepaticogastrostomy: results of a retrospective monocentric study. Endosc Ultrasound 2017;6:329-335.
- Khashab MA, Van Der Merwe S, Kunda R, El Zein MH, Teoh AY, Marson FP, et al. Prospective international multicenter study on endoscopic ultrasound-guided biliary drainage for patients with malignant distal biliary obstruction after failed endoscopic retrograde cholangiopancreatography. Endosc Int Open 2016;4:E487-496.
- Artifon EL, Aparicio D, Paione JB, Lo SK, Bordini A, Rabello C, et al. Biliary drainage in patients with unresectable, malignant obstruction where ERCP fails: endoscopic ultrasonography-guided choledochoduodenostomy versus percutaneous drainage. J Clin Gastroenterol 2012;46:768-774.
- Lee TH, Choi JH, Park Do H, Song TJ, Kim DU, Paik WH, et al. Similar efficacies of endoscopic ultrasound-guided transmural and percutaneous drainage for malignant distal biliary obstruction. Clin Gastroenterol Hepatol 2016;14:1011-1019.e1013.
- Paik WH, Lee TH, Park DH, Choi JH, Kim SO, Jang S, et al. EUS-guided biliary drainage versus ercp for the primary palliation of malignant biliary obstruction: a multicenter randomized clinical trial. Am J Gastroenterol 2018;113:987-997.
- Wagner HJ, Knyrim K, Vakil N, Klose KJ. Plastic endoprostheses versus metal stents in the palliative treatment of malignant hilar biliary obstruction. A prospective and randomized trial. Endoscopy 1993;25:213-218.
- Sangchan A, Kongkasame W, Pugkhem A, Jenwitheesuk K, Mairiang P. Efficacy of metal and plastic stents in unresectable complex hilar cholangiocarcinoma: a randomized controlled trial. Gastrointest Endosc 2012;76:93-99.
- Moole H, Dharmapuri S, Duvvuri A, Dharmapuri S, Boddireddy R, Moole V, et al. Endoscopic versus percutaneous biliary drainage in palliation of advanced malignant hilar obstruction: a meta-analysis and systematic review. Can J Gastroenterol Hepatol 2016;2016:4726078.
- Coelen RJS, Roos E, Wiggers JK, Besselink MG, Buis CI, Busch ORC, et al. Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol 2018;3:681-690.
- Lee TH, Moon JH, Choi JH, Lee SH, Lee YN, Paik WH, et al. Prospective comparison of endoscopic bilateral stent-in-stent versus stent-by-stent deployment for inoperable advanced malignant hilar biliary stricture. Gastrointest Endosc 2019;90:222-230.
- Lee TH, Kim TH, Moon JH, Lee SH, Choi HJ, Hwangbo Y, et al. Bilateral versus unilateral placement of metal stents for inoperable high-grade malignant hilar biliary strictures: a multicenter, prospective, randomized study (with video). Gastrointest Endosc 2017;86:817-827.
- Mocan T, Horhat A, Mois E, Graur F, Tefas C, Craciun R, et al. Endoscopic or percutaneous biliary drainage in hilar cholangiocarcinoma: when and how? World J Gastrointest Oncol 2021;13:2050-2063.
- Shim DJ, Gwon DI, Han K, Kim Y, Ko GY, Shin JH, et al. Percutaneous metallic stent placement for palliative management of malignant biliary hilar obstruction. Korean J Radiol 2018;19:597-605.
- Fu YF, Xu YS, Shi YB, Zong RL, Cao C. Percutaneous metal stenting for malignant hilar biliary obstruction: a systematic review and meta-analysis of unilateral versus bilateral stenting. Abdom Radiol (NY) 2021;46:749-756.
- Xia MX, Pan YL, Cai XB, Wu J, Gao DJ, Ye X, et al. Comparison of endoscopic bilateral metal stent drainage with plastic stents in the palliation of unresectable hilar biliary malignant strictures: Large multicenter study. Dig Endosc 2021;33:179-189.
- Kim JY, Lee SG, Kang D, Lee DK, Park JK, Lee KT, et al. The comparison of endoscopic biliary drainage in malignant hilar obstruction by cholangiocarcinoma: bilateral metal stents versus multiple plastic stents. Gut Liver 2021;15:922-929.
- Raju RP, Jaganmohan SR, Ross WA, Davila ML, Javle M, Raju GS, et al. Optimum palliation of inoperable hilar cholangiocarcinoma: comparative assessment of the efficacy of plastic and self-expanding metal stents. Dig Dis Sci 2011;56:1557-1564.
- Perdue DG, Freeman ML, Disario JA, Nelson DB, Fennerty MB, Lee JG, et al. Plastic versus self-expanding metallic stents for malignant hilar biliary obstruction: a prospective multicenter observational cohort study. J Clin Gastroenterol 2008;42:1040-1046.
- Choi JH, Lee SH, You MS, Shin BS, Choi YH, Kang J, et al. Step-wise endoscopic approach to palliative bilateral biliary drainage for unresectable advanced malignant hilar obstruction. Sci Rep 2019;9:13207.
- Iwasaki A, Kubota K, Kurita Y, Hasegawa S, Fujita Y, Kagawa K, et al. The placement of multiple plastic stents still has important roles in candidates for chemotherapy for unresectable perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2020;27:700-711.
- Hakuta R, Kogure H, Nakai Y, Kawakami H, Maguchi H, Mukai T, et al. Unilateral versus bilateral endoscopic nasobiliary drainage and subsequent metal stent placement for unresectable malignant hilar obstruction: a multicenter randomized controlled trial. J Clin Med 2021;10:206.
- Xia MX, Cai XB, Pan YL, Wu J, Gao DJ, Ye X, et al. Optimal stent placement strategy for malignant hilar biliary obstruction: a large multicenter parallel study. Gastrointest Endosc 2020;91:1117-1128. e1119.
- Cassani LS, Chouhan J, Chan C, Lanke G, Chen HC, Wang X, et al. Biliary decompression in perihilar cholangiocarcinoma improves survival: a single-center retrospective analysis. Dig Dis Sci 2019;64:561-569.
- Vienne A, Hobeika E, Gouya H, Lapidus N, Fritsch J, Choury AD, et al. Prediction of drainage effectiveness during endoscopic stenting of malignant hilar strictures: the role of liver volume assessment. Gastrointest Endosc 2010;72:728-735.
- Yoshida T, Hara K, Imaoka H, Hijioka S, Mizuno N, Ishihara M, et al. Benefits of side-by-side deployment of 6-mm covered self-expandable metal stents for hilar malignant biliary obstructions. J Hepatobiliary Pancreat Sci 2016;23:548-555.
- Hong W, Chen S, Zhu Q, Chen H, Pan J, Huang Q. Bilateral stenting methods for hilar biliary obstructions. Clinics (Sao Paulo) 2014; 69:647-652.
- Moryoussef F, Sportes A, Leblanc S, Bachet JB, Chaussade S, Prat F. Is EUS-guided drainage a suitable alternative technique in case of proximal biliary obstruction? Therap Adv Gastroenterol 2017;10:537-544.
- Minaga K, Takenaka M, Kitano M, Chiba Y, Imai H, Yamao K, et al. Rescue EUS-guided intrahepatic biliary drainage for malignant hilar biliary stricture after failed transpapillary re-intervention. Surg Endosc 2017;31:4764-4772.
- Kongkam P, Orprayoon T, Boonmee C, Sodarat P, Seabmuangsai O, Wachiramatharuch C, et al. ERCP plus endoscopic ultrasound-guided biliary drainage versus percutaneous transhepatic biliary drainage for malignant hilar biliary obstruction: a multicenter observational open-label study. Endoscopy 2021;53:55-62.
- Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020;21:671-684.
- Choi IS, Kim KH, Lee JH, Suh KJ, Kim JW, Park JH, et al. A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/ cisplatin chemotherapy. Eur J Cancer 2021;154:288-295.
- Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer 2020;147:2190-2198.
- Yoo C, Kim KP, Jeong JH, Kim I, Kang MJ, Cheon J, et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol 2021;22:1560-1572.
- Shinohara ET, Mitra N, Guo M, Metz JM. Radiotherapy is associated with improved survival in adjuvant and palliative treatment of extrahepatic cholangiocarcinomas. Int J Radiat Oncol Biol Phys 2009;74:1191-1198.
- Kim RD, Chung V, Alese OB, El-Rayes BF, Li D, Al-Toubah TE, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol 2020;6:888-894.
- Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol 2021;7:1669-1677.
- Phelip JM, Vendrely V, Rostain F, Subtil F, Jouve JL, Gasmi M, et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Federation Francophone de Cancerologie Digestive 9902 phase II randomised study. Eur J Cancer 2014;50:2975-2982.
- Pollom EL, Alagappan M, Park LS, Whittemore AS, Koong AC, Chang DT. Does radiotherapy still have a role in unresected biliary tract cancer? Cancer Med 2017;6:129-141.
- Shinohara ET, Guo M, Mitra N, Metz JM. Brachytherapy in the treatment of cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2010;78:722-728.
- Torgeson A, Lloyd S, Boothe D, Cannon G, Garrido-Laguna I, Whisenant J, et al. Chemoradiation therapy for unresected extrahepatic cholangiocarcinoma: a propensity score-matched analysis. Ann Surg Oncol 2017;24:4001-4008.
- Yi SW, Kang DR, Kim KS, Park MS, Seong J, Park JY, et al. Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer. Cancer Chemother Pharmacol 2014;73:191-198.
- Brunner TB, Blanck O, Lewitzki V, Abbasi-Senger N, Momm F, Riesterer O, et al. Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. Radiother Oncol 2019;132:42-47.
- Smart AC, Goyal L, Horick N, Petkovska N, Zhu AX, Ferrone CR, et al. Hypofractionated radiation therapy for unresectable/locally recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol 2020;27:1122-1129.
- Koo TR, Eom KY, Kim IA, Cho JY, Yoon YS, Hwang DW, et al. Patterns of failure and prognostic factors in resected extrahepatic bile duct cancer: implication for adjuvant radiotherapy. Radiat Oncol J 2014;32:63-69.
- Zhu HD, Guo JH, Huang M, Ji JS, Xu H, Lu J, et al. Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: a multicenter trial. J Hepatol 2018;68:970-977.
- Van Geenen RC, Keyzer-Dekker CM, Van Tienhoven G, Obertop H, Gouma DJ. Pain management of patients with unresectable peripancreatic carcinoma. World J Surg 2002;26:715-720.
- Xu X, Li J, Wu J, Zhu R, Ji W. A systematic review and meta-analysis of intraluminal brachytherapy versus stent alone in the treatment of malignant obstructive jaundice. Cardiovasc Intervent Radiol 2018;41:206-217.
- Dowsiriroj P, Paholpak P, Sirichativapee W, Wisanuyotin T, Laupattarakasem P, Sukhonthamarn K, et al. Cholangiocarcinoma with spinal metastasis: Single center survival analysis. J Clin Neurosci 2017;38:43-48.